SYRS - Earnings call transcript Q4 2018 | Syros Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen, and welcome to the Q4 2018 Syros Pharmaceuticals Incorporated Earnings Conference Call. [Operator Instructions] I would now like to introduce your host for today’s conference, Naomi Aoki, Vice President of Corporate Communications and Investor Relations at Syros. Please go ahead.

Naomi Aoki

Thank you. This morning we issued a press release with our fourth quarter and full-year 2018 financial results, along with anticipated future milestones and recent accomplishments. on www.syros.com. & available Syros’ section is at website release the Media Investors of This

begin call our for call our open Officer Chief will David will Chief our Medical Olson, are call We the and Q&A. Financial Chief and Nancy and by Officer; Officer; also Executive questions. Simonian, Officer. for Dr. Then, Officer; Ferra, Dr. Joe Roth, we Scientific the Chief the with our our will Business available prepared be Dr. Eric on Dr. Chief Jeremy remarks Springhorn,

everyone and filings Before we this call those we factors, of various of begin, statements with annual that forth report Actual Risk differ was I'd future. statements the the forward-looking or and Form include morning risks, the including on those the our in that make like events filed conference forward-looking Factors to implied this from XX-K, make a other results that any could remind with section materially as on on SEC result statements. in or we will expressed SEC other uncertainties set the by

any forward-looking views as be on forward-looking call I disclaim specifically the over today update revise this statements call to or only as not representing would represent any turn relied statements. subsequent and our should our to as to We date. made of upon now views addition, any In Nancy. of any like obligation

Dr. Nancy Simonian

in for SY-XXXX we XXXX expand progress trial clinical that we of programs data to our that this provide Most plan vision us announced and Thanks, and company medicines the confidence for and to profound added azacitidine great we Naomi. programs, achieving X us benefit of build ongoing enduring for both joining today. importantly, announced the These morning At we data Good SY-XXXX. everyone, is towards patients. Syros made our you morning, we vision. this who give and XXXX, thank with populations significant first-in-class the or refractory pharmacy our In a an and expansion a trial cohorts is clinical potential in Together these fast-to-market patient cohort platinum patients our these we’ve significant. ongoing a proof-of-concept. AML to agent replacing evaluating refractory cohorts. or unmet the programs. are these relapsed in for XXXX, the us the biomarker-positive. And need give rapid that The of cell primary both ovarian IRFX new relapsed into XXXX RARA serous provide And ovarian for cohort high-grade believe single potential cancer in clear with cohorts as recurrent combination added cancer, opportunities three Phase

priority on trials top is to of therapies with delivering patients as the much clinical quickly our as Our needed possible. execute aim to

foundation with earlier in this proof-of-concept of we the be setting, XXXX to the a us evaluated bring registration. Having MDS in for combination that towards current tolerability for a data efficient provided decision yard Let enable path active most unmet in to a drug to clinical by data ASH, landscape. to we strategy. the an XXXX patients for the this relapsed positioning from cohorts the cohorts that XXXX has AML evolving a our XXXX updated the our highly with in in we this in now believe plan market talking landscape favorable and AML midyear XXXX-aza enrollment of approvals strategy our at the the treatment and and year, me in the risk locations. exists the data pipeline. biomarker-negative start evolving Once patients. involvement or events, [ph] ongoing important expect in rapidly complete potential Based of positive clinical we these we’ve biomarker open for part development report potential unfit a Consistent higher to great in We These and is of and cohort biomarker-positive are provides MDS XXXX. unmet a diagnosed across quarter development AML need landscape, new and and many move need with overall the agents for highest biomarker-positive population profile cohort significant combination ANL newly potential reported third the vision remains a Despite year, multiple on development, biomarker-positive to December guidance the care AML believe the broadly second half we could patients. about and refractory

development clinical be a cohorts data In diagnostic companion commercial addition, from of could in these potential launch. the the a for valuable in time

me let patients. there rationale clinical for she pipeline escalation is in response who shrank clinical. these patients moment little with for XX% XXXX, tumor clear very with and ovarian existing remission cancer XXXX. partial clear pursuing told our we dose cancer for our prognosis prior represents of discuss the cancer recurrent a take her of approximately in lines tumor is cancer ovarian In to Turning ovarian had to cell Clear to and with of respond therapies dismal. durable portion her Few three cell the cell had cried. patient doctor whose cell a the trial, to never a clear When was that but shrinking, her therapy,

work time in our As the months. her and underscore we the of six importance at like do Stories through her every what presentation and November XX% tumor had shrunk been At day. to and all urgency has hers data inspire us of sustained do the response best by Syros

escalation, be tremendous patients XXXX cancer in believe the this difficult in very expect the clear data the focus the these proof-of-concept dose and new ovarian cohort we for cancer and potential unmet to warrants the from We in enrollment on data believe XXXX. patients puts to in Given cell second quarter. timing us open track treat investigation on further our existing need, for

will cohort could for determine this believe foundation cell, positive the accelerated the in opportunity. filing data form our if given clear steps, unmet an next we the need ultimately While high

new or have ongoing a prior also of need addition, dire the population lines more high-grade Consistent of our an patient gives third X cohort Phase in for and in fourth a and three patients serous for initial path. ovarian In in proof-of-concept therapy earlier we the the opportunity cancer relapsed us development rapid with had of to provides who expect report guidance, portion the therapies accelerated opportunity an from expansion data trial quarter.

safety in report data patients three ovarian the with Specifically, safety PK from data the the evaluating of ongoing cancer carboplatinum initial cohorts, mentioned efficacy or solid therapy, and ovarian we lines with prior advanced from of to in prior expect I cohort in three just assessment patients and with patients cancer including initial have from data from had cohort combination and cohort XXXX one tumors. mechanistic in and biopsy of safety the therapy, efficacy, who more lines

from CDKX/X report to in cohorts cancer as expect the proof-of-concept resistant inhibitor patients initial cell data additional from clear the We in these HR well cohort for data XXXX. the breast positive as data and

CDKX is believe maintain together CDKX where the more Moving to and therapies highly oral We as XXXX, could to a a and with having combining It year into or and SY-XXXX, is last part our in complementary of strategy our to as development potent other many distinct oral our for and treatment as seamlessly that key of particularly you franchise a next and inhibition. see such on powerful build a leadership study. inhibitor oral XXXX XXXX XXXX fits administration XXXX make opportunities we we when selective CDKX know candidate. in paradigm and selected maintenance

and potency We at XXXX presenting the the activity be will new data selectivity, AACR antitumor meeting. on upcoming preclinical of

our of We of advance continue in to next a years and expect enabling our XXXX. to for year, three am control to molecule promise I this clinical expression thrilled in early to Phase molecule, rich track next which have is towards genes. we initiation I his for XXXX this and really what's come. credit and a that discovering expertise be to to By team Eric to remain IND inaccessible support selective This studies Olson the in developing X oncology targets of drugs speaks year the development to time clinical XXXX. with XXXX this want year development. on exquisitely and and historically get about to and complete excited progress trial lot data programs small

earlier cell cohorts year on to cancer three potential in ovarian AML, turn across ovarian refractory or positive prior CDKX/X ongoing lines with both breast eight trials ovarian population. David be recurrent provides while in cancer data programs, With our next. or review readouts over and the resistant in to detailed path move treatment clear to opportunities this executing strategies of line relapsed let cohort expect into X for cancer gives combination me market growing in plus and inhibitor diseases and to patients call cohorts cohorts us more that, We cancer two HR all programs. patient in eight relapsed clinical with of The the for in a carboplatinum from

Dr. David Roth

morning philosophy start clinical the on development describing would to good and today Nancy, by everyone I Thanks, to call. like more our broadly.

believe philosophy data on to aim for for putting to we and respond agents when plans providing to shifting data-driven so First greatest and pursue on patients. patient cases simultaneously that likelihood and and to a based in that for there's our We today be other relating in look rapidly patient or a foremost, dynamics. therapies most a indications in candidates the we action. And were strategy single honing patients take that signal design clinical just identify benefit approach responders. multiple of early exemplify selection our XXXX we can we profound platform biomarkers and we're for likely XXXX into in to how enrich positive combination populations. our using out The our opportunities strategies respond flexible, and trials drug explore some development both to on We market we see as development our

number Based XXXX. diagnosed Realizing data unfit XXXX unique eight CRI. rapid key and onset an cohort and tolerability combination relapsed with in achieving Across we overall of the our newly we is MDS patients. in CR evaluable AML X activity XX% AML AML therapies, data patients. the combination profile strategy ongoing higher the data AML that of response response XX% to either trial or to demonstrated biomarker-positive patients, synergy presented of patients on development clinical XXXX-aza a ASH, in and in or preclinical on a believe in response the newly Turning rate refractory rate These of potential Phase patients. MDS potential clinical to announced initial high biomarker-positive patients. broad starts with December, that observed At risk a and date, clinical and with has its we

treatment. These our single of responses compare from most at well as month favorably azacitidine end the the as data to early of cohorts. negative to Additionally, were seen data first the agent biomarker

when as the no combination seen biomarker-positive We remain be gather and ongoing unfit data elderly the to treatment more in committed delays. treat the mature AML believe the to of Importantly we morbidity tends expected tend And which Of the in a there for to a diagnosed XXXX enrollment tolerated combination often newly the in myelosuppression, note, to place That reductions made completing rapidly evidence cohorts agent patients. trial. patients, related of clarify for no alone. dose embarked more AML and combining potentially is path the was our challenging be when there evolving drugs of treatment in development it landscape increased increased with agent well ultimately we these and was toxicities in generally beyond next to treatment said, than has steps result this would was each which upon and patients to who leukemia population. longer with and this that which may frail,

to data of preliminary the or rapid proof-of-concept cohort potential XX patients in to and trial form the path. at data combined new X biomarker-positive Phase patients, we a have potential to plan where have expect MDS landscape XXXX. refractory basis decision AML opportunity and expand the the the We with AML proof-of-concept enroll and in into for accelerated filing ongoing relapsed Our emerging our

completed XXXX. with inhibitor resistant decided moved initial on cancer turn HR for types need We trial. expansion data solid several in relapsed more into escalation and to We let trial Phase believe cancer. to We dose in of unmet portion a for and in and the high. tumors focus was the September those the CDKX/X me treatment cancer tumor potentially transformative X CDKX patients of targeted Now the broadly, inhibition strong advanced XXXX, portion approach preclinical The ovarian represents and the positive the of the expansion breast reasons.

an also alterations a based on showing RB be and these cancer. ovarian in respond why and association prevalent XXXX cancer known to had are mechanistic in be to which for We breast data likely resistant inhibitor the pathway, responses might in rationale between patients more CDKX/X

inhibitors. selective clinical data reported neutropenia, which And demonstrated for generally on presenting from were associated At response will the pan-CDK were preclinical proof has be and mechanism at manageable. the models reported CDKX on SY-XXXX alterations these November, data cancer The this in upcoming the new We association RB dose ovarian the signs reversible data importantly, at to predominantly been no were AACR data a inhibitor. meeting there doses. with in Adverse the of EORTC-NCI-AACR of tolerable between and data Notably, the past low meeting. grade, first escalation. XXXX CDKX/X we events

of early to tumor saw any the that patients had patients data had were escalation and very escalation X the in is activity of in at advanced the signs doses who the in were activity. as dose patients partial October, who pretreated dose refractory. given of clinical oncology saw of be particularly sub-therapeutic. whom histology and to disease. We response This of response cutoff highly study, typical heavily anticipated us and valuable including clinical in as X was were treated stable to XX a exciting one solid also was and We a confirm sick Many

of recurrent on Fewer warrants activity free ovarian and earlier, is of ovarian mentioned population. early With in patient progression signal patients unmet single to The respond horizon cell confirmed in recurrent focused Based a Nancy cancer. cell, is clear there investigation patients. these clear partial assess cohort X of cancer cell, this the a cell handful and XX% XXXX agent. X As months. clinical for clear further on need to XXXX believe this response therapies ovarian the clear the little in survival on only existing a cell within with we clear recurrent will than trials as only

will based an from be expect our could from leading data proof-of-concept. patients We approximately XX ovarian positive, accelerated development if support and strong cancer second plan potential expected we it rapid in XXXX, And data experts, we the also the quarter on in for believe be are open to have and there with to input we investigators, path. believe there's the enroll for enrollment

patients best potential high-grade of lines ongoing existing the treatment exhausted market and are plus assessing have single opportunity resistant cohort to have as had patients is other Many a for in XXXX prior XXXX options. Our agent of relapsed who serous these ovarian treatment. X platinum cancer

fourth XXXX. to in So have and cohort in potential quarter from we data the this proof-of-concept data initial expect

this cohort. will believe based significant the cohort unmet fast-to-market accelerated and The refractory When be we with there clear need included portion an if of platinum As the cell to potential positive, the we the data a be cohort, we could the designed development cell strategy. are path. trial, its cohort the clear expansion primary replace on

approval fast-to-market however, refractory. focus recent of as clinical potential which believe with fewer our bevacizumab on are the meeting primary strict Syros. and definition combination cancer, for and patients we the ovarian we’ve a for carboplatin, cell such, Given opportunity recurrent superior clear resources patients for platinum And to decided being efforts provides in

full-year call to to for you results Joe would XXXX. quarter keeping busy And the and with populations our our in review fourth be ones programs look desperately like proof-of-concept will With years readouts potential for that therapies. data our Joe? progress. to few on updated next that, the here, turn better patient outlined the I we’ve to over As forward I for financial need us several

Joe Ferra

platform leading long-term allowing milestones, Thank position. from into XXXX, our our our existing to also and programs our key continues strong stage CapEx operate cash, of to to fuel clinical planned cash support gene that in quarter believe will in our a you, Syros us David. control and advance We securities the while financial equivalents marketable pipeline second investing and earlier growth. to operations

research expenses. employee for This as $XX.X the Now an fourth compared as XXXX of million primarily for the for the in million cash, clinical same due million This ended fourth $XX.X our to the earned due in for costs the under increase $X.X recognized revenue full-year equivalents million in an million as XXXX. in increase related XXXX securities full-year were $XX.X for well $XX.X and XXXX the $XX.X period XXXX. our XXXX to in G&A of the were million $XX.X for collaboration and full-year were million G&A XXXX $XX financial $XX.X primarily compared XXXX. expenses entirely the the in million revenue quarter for as in a to XX, increase for XXXX. any support million was XXXX agreement trials for were $X.X for $X.X Revenues fourth R&D compared full-year with Incyte, from on million the with to full-year to XXXX to expenses million as professional compared not compared quarter our while record million in were quarter fees manufacturing increase as R&D contract to compared period XXXX. the employee for in expenses related was expenses do expenses. in full-year of XXXX. $X.X We for XXXX. an same $X.X increase and XXXX. with our of revenues multinational cash Revenues the were fourth XXXX XXXX December We million for We fourth pharmaceutical company. were full-year results. earned quarter our with marketable of quarter

million a same the period per share to compared for in the $X.XX per net $XX net share $XX.X $X.XX quarter for or Finally, of fourth XXXX. loss a of we or loss reported million

full-year loss was For questions. full-year for With net Thank to you. the $X.XX or $XX.X XXXX. that, net share our turn over per $X.XX for share to to of a operator now $XX per XXXX, the the million loss like would or million the compared call I

Operator

from Thank question comes you. Nadeau our And first Cowen Company. Phil [Operator Instructions] with and

line Your is now open.

Phil Nadeau

for morning. my taking questions. Good Thanks

the on talk could enrollment they that particular, Can azacitidine bit relapsed have about azacitidine arm be for about First and -- the arm prior a XXXX you where patients before naive question the arm? to to get In more AML. into criteria or little enrollment? refractory the seen have azacitidine plus

Dr. David Roth

question. patient being patients criteria or have would and the -- specific thanks the patients to prior for AML Yes, be The for there meet refractory patients. no the exclusion HMA exposed for relapsed will and

Phil Nadeau

Got it.

second, maybe Okay. then, rationale a can but data partially you the about It from for more talk remarks, prepared partially arm. like seen, we’ve adding it's that then also sounds little the bit that the your curious kind predominates? I’m evolving those And the Which is how you’ve those is landscape. competition coming in data seen more was which -- of elements important, AML? naive it just or elements of And

Dr. Nancy Simonian

think that safety favorable in seen well I excited as we've as activity really XXXX really ongoing the of combination in profile. about the diagnosed unfit newly level azacitidine we're the

the in think have be thinking drug population. I how what the to about to unfit market best and it the get we and newly data really I more think the way the that’s a thing and to be we will predominant. initially -- evolving And But will what’s the are that diagnosed that most that in landscape we’re key setting get the think refractory. new excited efficient the we to in recent develop always the with in path to approvals path that is about market, efficient relapsed

Phil Nadeau

it. Got

guess, refractory but cell cell? is lot you of I the you many makes the what missed find then proportion change how cell, about the refractory, clear you patients? in that’s platinum to platinum of clear were And that second hard patients Could reiterate it just I’m And first, of the curious XXXX that I the trial, ovarian just That it. then one said question clear do is, proportionate Okay. a sense. on really both actually plus mentioned

Dr. David Roth

Yes.

Phil. thanks, again, So,

increasingly respect patients carboplatin. with as clear the to at has So to XX% setting earlier, bevacizumab cell. have the for the -- ovarian in estimated in pivot proportion clear combination of mentioned about reason the early with been of cancer And I utilized with cell, is the with approval

therapy. requires so after progression line those criteria. fewer completing of And definition And fewer refractory patients seeing month in of we’re during that primary and or a the platinum within initial of

have clinical those an So of for opportunity patients. early patient I refocus another that a mechanistic and unmet can think we there gives is our in significant to that us make need that efforts population we difference belief a activity rationale where signal

Phil Nadeau

got it. on for Thanks is I the clear. taking my and That very progress. questions congrats

Dr. Nancy Simonian

Thanks, Phil.

Operator

line next our question of Piper Jaffray. with from comes And Ted the you. Tenthoff Thank

open. now is line Your

Ted Tenthoff

is Great. up in Thanks the My two there a more tell were much mechanistic us between very of ovarian. be just rationale some much sales. the a cell actually a XXXX the the there biological two What better little progress and congrats solid maybe clear picking applied on is bit Is or really of differences? on across question programs. about difference might

Dr. David Roth

Okay.

we’ve patients pathway again, RB serous in clear show may SY-XXXX. for look features and there molecular demonstrated data ovarian are them. that at predict previously that high-grade are you to sensitivity cell So, When different distinguish important alterations that

function well [technical difficulty]. as genetic alterations lead cell altered RB However, to cycle also as that they --

mutations those partial the of during response who cell the mutations our escalation ARIDXA include mutations. of PIKXCA and well Some with interestingly patients have mutations dose both had as clear those confirm as

works. The last there's patients clinical really just [indiscernible] point very are we think And an the feel early evaluation. activity have now responses there's short-lived. follow-up that such a is signal typically we but the need. -- that only to unmet mechanism So further and because a not the significant clinical on chemo-resistant are mechanistic we rationale, little think we These compelled support

-- proof-of-concept another rapid for clinical registration opportunity. and again, accelerated So, it an opportunity gives proof-of-concept us

it. that’s really So pursue think compelling very to we rationale all

Ted Tenthoff

Makes a lot detail. of sense. for Thanks that additional

Operator

from comes Mark the with Oppenheimer. line our Thank question you. And of next Breidenbach

Your is now line open.

Mark Breidenbach

progress. the question, the taking for thanks and and recent congrats morning on Good

lessons to I’m you. trying also Maybe the into are wondering get cohort refractory just if to the as that the relapsed announced or clear be in used what new could support streamline to And registration you’re that question David, enrollment to in to bar back viewing the setting. for with AML. for a just sense learned you refractory you relapsed cohort efficacy combination that going want in So XXXX Thank guide any patient daratumumab today? there the

Dr. David Roth

Okay.

So I start with background. will the

proof-of-concept So in the cohort. to the at terms the need as we're of product profiles be things at -- -- looking as developed. in that’s we our and have going And and activity rates, that various unmet well believe we're very response anticipating look at parameters seeing target and to relative durations tolerability. we safety we’ve has We to in and a very, look that landscape diagnosed the that response tolerability. comparing response for XXXX, how well-tolerated We combination that newly how

responses you look If at the relapsed are population, rather low.

timeframe. the instance, for rate responses have in durations agent XX% the who single response with relapsed in Aza get response patients range X-month typically a as So approximately

agents of Some response durations maybe been bordering targeted about have recently the rates, X inhibitors X XX% FLTX similar the or for to maybe CR that the IDH months. approved have

And the question are those the results backdrop we calibrating So was that specific related framework the just that? to about you daratumumab. then our repeat general question the be will of second against. Could

Mark Breidenbach

into setting, refractory enrollment that help patient there's to if from that already if we that’s streamline learn there's we’ve wondering just from Yes, that we anything study the that new where tested cohort the can can relapsed since seen extract cohort? anything in XXXX

Dr. David Roth

Yes.

daratumumab So XXXX well with significant prior I combination our experience need. agent single think as with as that the track our unmet really experience with

We equally high. our high from is expect also support be need therefore there of expect this relapsed And feedback investigation. finding and unmet the investigators, the our to confidence is on and we’ve to the actually so already don't majority patients approach we challenges received

Mark Breidenbach

thing, types in that best response transferable of that be directly biomarker information from which of patients terms But no cohort? Okay. for of candidates sort might

Dr. David Roth

Right.

looking at RARA patients. are biomarker-positive IRFX and We or

Mark Breidenbach

right. All you. Thank

Operator

from with Jotin [Operator And Marango next comes the you. ROTH of question line our Capital. Instructions] Thank

Your open. line now is

Jotin Marango

Good questions. thinking in my my morning. around XXXX the itself. disease, on question have Thank you taking each I two When for population is program. of about the myeloid

disease have Over you these insight different last it of clinically or respond differently is biomarker-positive year So biomarker-positive disease type have do or level? a the to the that patients gained patients other course morphological on have the any of treatments?

Dr. David Roth

good question. a That’s Okay.

at molecular level we and might at our expect very presentation So And unselected with that carefully. the mutations out We of the all types in I typical at than abnormalities that look in see half high patients of our and a pointed poor clinical cytogenetic one a those population all ASH, response and treatment. the cytogenetic more had count number, majority enrolled biomarker-positive to risk had complex predictors poor of blast features fair very or AML, of of are AML.

in saw we So response that XX% that fact population the the in overall confidence conviction and this patient program. rate very challenging increases our

Jotin Marango

thinking about enriched this HMA headed this or moves are are And cohort David, the blast year. it Is with you as the disease biomarker-positive on if follow-up next patients relapsed therapy? point that, population, the combo when a it. at later to the around Got clear

Dr. David Roth

populations So we’ve study. for that positivity the over time the across approximately screened found consistent -- a XX% rate biomarker we’ve

find percent And relapsed this for the we population. think similar in so, will we a that patients of

Jotin Marango

AACR Okay. Switching to couple there in CDKX from XXXX, the last release was you. of on data

interesting disease target. one? implication that downstream and this as there In at plans MCLX or direction going next with to I some at gen is point in the of fact, molecule either Any well even was think target myeloid this

Dr. Nancy Simonian

potential XXXX in oral strong are potential compound heme the as across forward, -- certainly with tumors and Yes, inhibitors. both Nancy. CDKX data And well is worth as malignancies about thinking coming This some solid Jotin. heme very Hi, we about thinking future are obviously it's there our development the both broader malignancies. XXXX of

Jotin Marango

Okay.

positive the is cohort, you about a what year ovarian data? just or bar, tumor have you will clinically efficacy hear then, we represent the your as have later what it so data which set data move Is we trickles internal indicators meaningful what towards this So reductions response that in? bar? the will On of as as

Dr. Nancy Simonian

in we benchmark some about populations, Jotin, for that of as we’ve -- those forward. see our to in what of compelling to it that trial, we So, we the and move population cohorts enough data said and look we profiles is agents set criteria feel patient at develop this in kind each be targets like against historical internally we want -- we the other order we'd with to

precedence So we specifically talk in approach. about about you don't that’s but to the population David, haven't so for numbers -- those what know be? I each, talked want will the that

Dr. David Roth

low there's clinical agent progression-free and we in low Well, the their as clear response and three signal then very and short well think the high-grade can approach. of evaluation in identified because the translate an line response. response why which are low looking plus durations into cell, fast-to-market into easily -- -- that of We comfortable those and at serous, -- basically as an that’s single yes, as translate rapid should mean, accelerated I PoC for clinical that fast we registration survival, rates short XXXX, opportunities rates

Jotin Marango

all at See AACR. much. very Thanks you

Dr. Nancy Simonian

Jotin. Thanks,

Operator

Nancy any like Thank call remarks. does question-and-answer you. the turn conclude further that Simonian And today’s for to I'd now session. back to

Dr. Nancy Simonian

accomplished am for we’ve all you Syros. in And proud continued interest Thank everything in you, I XXXX. and operator. support your thank of

look and to becoming accomplishments benefit for medicines thank beyond, and provide XXXX multiple forward that a progress to laid XXXX, our updated patients. integrated milestones vision company in you. with profound the keeping promise to closer us We fully of you for these Importantly, a clinical that on groundwork bring our

Operator

program. for today’s you conference. thank gentlemen, conclude today’s participating and This in Ladies does

You a may Everyone day. disconnect. all great have

Syros Pharmaceuticals (SYRS) 7 Mar 192018 Q4 Earnings call transcript